( 19 ) United States ( 12 ) Patent Applicati0n Publicati0n mm Pub. N0. : US 2006 / 0178426 A1. Stahle et al. ( 43 ) Pub. Date : . US 20060178426A1. Aug. 10 , 2006. . ( 54 ) . ( 76 ) . ( 21 ) ( 22 ) ( 86 ) . ( 30 ) . KAPPA AGONISTS , ESPECIALY FOR THE TREATMENT AND / OR PROPHYLAXIS 0F IRRITABLE BOWEL SYNDROME. 1nVent0rs : W0lfgang Stahle , 1nge1heim ( DE ) ; Rud0lf G0ttschlich , Reinheim ( DE ) ; Jurgen Harting , Darmstadt ( DE ) ; Christ0ph Seyfried , Seeheim - Jugenheim ( DE ) . C0rresp0ndence Address : . MILLEN , WHITE , ZELANO & BRANIGAN , P. C. 2200 CLARENDON BLVD. SUITE 1400. ARLINGTON , VA 22201 ( US ) . App1. N0. : 10 / 563 , 975 PCT Fi1ed : Jun. 18 , 2004 PCT N0. : PCT / EP04 / 06630 F0reign Applicati0n Pri0rity Data. Ju1. 11 , 2003 ( DE ) . 103 31 723.6. ( 51 ) . ( 52 ) ( 57 ) . Publicati0n Classiﬁcati0n. Int. Cl. A61K 31 / 4015 ( 2006.01 ) . C07D 207 / 46 ( 2006.01 ) . U. S. Cl. . 514 / 424 ; 548 / 542 ABSTRACT. C0n1p0und 0f the f0nnu1a ( I ) , in Which A , R1 , R2 , R3 , X , Y , m and n haVe the meaning indicated , are suitab1e as f0r the treatment 0f irritab1e b0We1 syndr0me. I \ R3 ( R‘ ) m—| 111 N—X—Y—A / I x j 0 / / N \<R2 ) n HO. US 2006 / 0178426 A1. KAPPA AGONISTS , ESPECIALY FOR THE TREATMENT AND / OR PROPHYLAXIS OF IRRITABLE BOWEL SYNDROME. [ 0001 ] 1. The inVenti0n re1ates t0 c0mp0unds 0f the f0rmu1a. \ 3 ( R1 ) m©j / : / N—X—Y—A W1 0 / . HO. [ 0002 ] . [ 0003 ] A den0tes a m0n0 - 0r bicyc1ic ar0matic 0r n0n - ar0matic carba - 0r heter0cyc1ic ring system Which is unsubstituted 0r m0n0 - 0r p01ysubstituted by R1 , . [ 0004 ] R1 den0tes H , Ha1 , NO2 , NHR , NRR , OR , CO—R , SO3R , SO2R , SR , CF3 , OCF3 , SCF3 , C1 - C8 a1ky1 , C3 - C14 cyc10a1ky1 , . [ 0005 ] R2 den0tes H , Ha1 , NO2 , NHR , NRR , OR , CO—R , SO3R , SO2R , SR , CF3 , OCF3 , SCF3 , C1 - C8 a1ky1 , C3 - C14 cyc10a1ky1 , R3 den0tes C1 - C8 a1ky1 , . [ 0006 ] X den0tes CO , CS , SO2 , [ 0007 ] Y den0tes a sing1e b0nd , O , NH , CH2. [ 0008 ] R den0tes H 0r a C1 ' C8 alky1 , C3 - Cl4 cyc10a1ky1 , C6 ' C1o ary1 0r C7 - Cl4 ara1ky1 gr0up , Which may be m0n0 - 0r p01ysubstituted by RS and Wh0se a1ky1 - C chain may be interrupted by —O— , . [ 0009 ] Ha1 den0tes F , C1 , Br , 0r 1 [ 0010 ] [ 0011 ] and [ 0012 ] . [ 0013 ] and / 0r 0ne 0f their physi010gica11y acceptab1e sa1ts and / 0r 0ne 0f their g1yc0sy1ated deriVatiVes. [ 0014 ] C0mp0unds haVing a simi1ar structura1 f0rmu1a and suitab1e pr0cesses f0r their preparati0n are described in DE - A 198 49 650 , DE 40 34 785 and DE 4215 213. The use 0f simi1ar c0mp0unds f0r the treatment 0f inﬂammat0ry intestina1 diseases is disc10sed in EP 0 752 246. 1t Was an 0bject 0f the inVenti0n t0 pr0Vide pharmaceutica11y effectiVe c0mp0unds Which can be emp10yed and are effectiVe , in particu1ar , in the treatment and / 0r pr0phy1aXis 0f irritab1e b0We1 syndr0me ( IBS 0r c010n irritab1e ) Which simu1ta - ne0us1y ame1i0rate the pain ass0ciated With this disease and cure the disease. in Which. m den0tes 0 , 1 , 2 , 3 0r 4. 11 den0tes 0 , 1 , 2 0r 3 , . [ 0015 ] At the same time , it Was an 0bject 0f the inVenti0n t0 pr0Vide pharmaceutica11y eﬁectiVe c0mp0unds Which haVe n0 eﬁects 0n n0rma1 intestina1 perista1sis , but c0ntrib - . Aug. 10 , 2006. ute t0 the curing 0f irritab1e b0We1 syndr0me. 1BS is the c0mm0nest cause 0f abd0mina1 pain syndr0mes. [ 0016 ] Preferred c0mp0unds 0f the f0rmu1a 1 are kappa ag0nists , in particu1ar periphera11y acting kappa ag0nists , and are theref0re suitab1e f0r the treatment 0f diseases Which , as is kn0Wn , can be inﬂuenced by kappa ag0nists , such as , f0r examp1e , pruritus ( U . S. Pat. N0. 6 , 004 , 964 ) . The c0mp0unds are 1ikeWise suitab1e as ana1gesics. [ 0017 ] 1t has n0W been f0und that c0mp0unds 0f the f0rmu1a I. I \\‘ R3 ( R1 ) m_| I N—X—Y—A / N l \ / j 0 / N ' A08 ) HO. in Which A , R1 , R2 , R3 , X , Y , m and n haVe the meanings indicated ab0Ve and / 0r physi010gica11y acceptab1e sa1ts there0f and / 0r g1yc0sy1ated deriVatiVes there0f , are pharmaceutica11y actiVe c0mp0unds Which are particu1ar1y suitab1e as kappa ag0nists and actiVe ingredients in medicaments f0r the treatment 0f irritab1e b0We1 syndr0me. 1n particu1ar , preference is giVen t0 c0mp0unds 0f the f0rmu1a IA. I \\‘ R3 R%rT ' / / [ N—x—u—a \ _ \ € ; : : : ] / / / <R0n. HO. in Which A , R1 , R2 , R3 , X , Y , m and n haVe the meanings indicated ab0Ve. Very particu1ar preference is giVen t0 c0mp0unds 0f the f0rmu1a I and 1A. [ 001s ] . [ 0019 ] A den0tes pheny1 , pyridy1 , thieny1 0r cyc10hexy1 , each 0f Which is unsubstituted 0r m0n0 - 0r p01ysubstituted by Rl , . in Which. [ 0020 ] R1 den0tes H [ 0021 ] R2 den0tes H 0r Ha1. [ 0022 ] Preference is a1s0 giVen t0 c0mp0unds 0f the. : mnnma1andLAn1Whmh [ 0023 ] [ 0024 ] . A den0tes pheny1 0r naphthy1. and / 0r. US 2006 / 0178426 A1. [ 0025 ] . [ 0026 ] . [ 0027 ] [ 002s ] . [ 0029 ] Besides the c0mp0unds 0f the f0rmu1a 1 , the inVen - ti0n thus re1ates t0 the use 0f the c0mp0unds 0f the f0rmu1a I as medicaments f0r the treatment 0f diseases Which can be inﬂuenced by kappa ag0nists , and in particu1ar 0f irritab1e b0We1 syndr0me. The present app1icati0n a1s0 re1ates t0 c0mp0siti0ns Which c0mprise c0mp0unds 0f the f0rmu1a I as c0nstituent f0r the treatment and / 0r pr0phy1axis 0f irritab1e b0We1 syndr0me. [ 0030 ] EXperiments haVe sh0Wn that the c0mp0unds acc0rding t0 the inVenti0n act 0n mice 0r rats in the “Writhing test” ( meth0d cf. Siegmund et. al. , Pr0c. SOC. Exp. Bi01. 95 , ( 1957 ) , 729 - 731 ) . The ana1gesic acti0n as such can furtherm0re be dem0nstrated in the “tai1 - f1ick test” 0n mice 0r rats ( meth0d cf. &Am0ur and Smith , J. Pharmac01. Exp. Ther. 72 , ( 1941 ) , 74 - 79 ) , furtherm0re in the “h0t p1ate test” ( cf. Schmauss and Yaksh , J. Pharmac01. Exp. Ther. 228 , ( 1984 ) , 1 - 12 and the 1iterature cited therein ) . Particu1ar1y str0ng acti0ns can be 0bserVed in rats in the m0de1 0f carrageenin - induced hypera1gesia ( cf. Bart0szyk and Wi1d , Neur0science Letters 101 ( 1989 ) 95 ) . The c0m - p0unds eXhibit n0 0r an 0n1y s1ight tendency t0Wards physica1 dependence here. [ 0031 ] by c0mm0n meth0ds haVe sh0Wn pr0n0unced antiinﬂammat0ry , diuretic , antic0nVu1siVe , neur0 - pr0tectiVe acti0ns. The c0mp0unds eXhibit high aﬁinity With respect t0 the binding behaVi0ur t0 kappa recept0rs. [ 0032 ] 1n c0ntrast t0 0ther c0mp0unds haVing a simi1ar actiVity spectrum , c0mp0unds 0f the f0rmu1a 1 are particu - 1ar1y suitab1e f0r use in pharmaceutica1 c0mp0siti0ns f0r the treatment 0f irritab1e b0We1 syndr0me since , besides the ana1gesic and antiinﬂammat0ry acti0n , they are suitab1e f0r n0rma1ising impairments in the intestina1 m0t0r system caused by the disease. [ 0033 ] 1n additi0n , it has pr0Ven particu1ar1y adVantage0us in the case 0f the c0mp0unds acc0rding t0 the inVenti0n that , 0Wing t0 their structure , they are apparent1y unab1e t0 pass thr0ugh the b100d / brain barrier and theref0re haVe n0 dependency p0tentia1. [ 0034 ] The c0mp0unds 0f the f0rmu1a 1 , they are , in additi0n , distinguished by the fact that , 0Wing t0 their pharmac0kinetic pr0perties , such as , f0r eXamp1e , a 10gD Va1ue <—1.5 0r a Very 10W s01ubi1ity 0f 1ess than 0.01 m01 / 1 , they can 0n1y be ab s0rbed t0 an extreme1y 10W pr0p0rti0n 0r n0t at a11. They are theref0re predestined f0r10ca1 use in the intestine. [ 0035 ] 1n additi0n , n0 eﬁects haVe hithert0 been f0und Which W0u1d in any Way restrict the use 0f the adVantage0us e1fects f0r the c1aimed indicati0ns. [ 003 6 ] The c0mp0unds 0f the genera1 f0rmu1a I and physi - 010gica11y acceptab1e sa1ts there0f can theref0re be used f0r. X den0tes CO 0r SO2 , in particu1ar SO2 and / 0r Y den0tes a sing1e b0nd 0r NH. Ha1 preferab1y den0tes F , C1 0r Br , in particu1ar C1. 1n additi0n , c0rresp0nding eXperiments carried 0ut. Aug. 10 , 2006. the preparati0n 0f pharmaceutica1 preparati0ns by bringing them int0 the suitab1e d0sage f0rm t0gether With at 1east 0ne eXcipient 0r adjuVant and , if desired , With 0ne 0r m0re further actiVe ingredients. [ 0037 ] The inVenti0n theref0re a1s0 re1ates t0 a pharmaceutica1 c0mp0siti0n , characterised by a c0ntent 0f at 1east 0ne c0mp0und 0f the f0rmu1a 1 and / 0r 0ne 0f its physi010gi - ca11y acceptab1e sa1ts f0r the treatment 0f irritab1e b0We1 syndr0me. [ 0038 ] The c0mp0siti0ns 0btained in this Way can be emp10yed as medicaments in human 0r Veterinary medicine. Suitab1e eXcipient substances are 0rganic 0r in0rganic substances Which are suitab1e f0r entera1 ( f0r eXamp1e 0ra1 0r recta1 ) 0r parentera1 administrati0n and d0 n0t react With the n0Ve1 c0mp0unds , f0r examp1e Water , Vegetab1e 0i1s , benzy1 a1c0h01s , p01yethyene g1yc01s , g1ycer01 triacetate and 0ther fatty acid g1ycerides , ge1atine , soya 1ecithjn , carb0hydrates , such as 1act0se 0r starch , magnesium stearate , ta1c 0r ce11u - 10se. [ 0039 ] Suitab1e f0r 0ra1 administrati0n are , in particu1ar , tab1ets , dragees , capsu1es , syrups , juices 0r dr0ps. Of particu1ar interest are ﬁ1m - c0ated tab1ets and capsu1es haVing gastric juice - resistant c0atings 0r capsu1e she11s. Suitab1e f0r recta1 administrati0n are supp0sit0ries , suitab1e f0r parentera1 administrati0n are s01uti0ns , preferab1y 0i1y 0r aque0us s01uti0ns , furtherm0re suspensi0ns , emu1si0ns 0r imp1ants. [ 0040 ] The actiVe ingredients c1aimed in acc0rdance With the inVenti0n may a1s0 be 1y0phi1ised and the resu1tant 1y0phi1isates used , f0r eXamp1e , f0r the preparati0n 0f inj ec - ti0n preparati0ns. [ 0041 ] The c0mp0siti0ns indicated may be steri1ised and / 0r c0mprise adjuVants , such as preserVatiVes , stabi1isers and / 0r Wetting agents , emu1siﬁers , sa1ts f0r m0difying the 0sm0tic pressure , buffer substances , dyes and / 0r ar0ma substances. 1f desired , they may a1s0 c0mprise 0ne 0r m0re further actiVe ingredients , f0r examp1e 0ne 0r m0re Vitamins , diuretics , antiph10gistics. [ 0042 ] The c0mp0unds 0f the f0rmu1a I acc0rding t0 the inVenti0n are genera11y administered ana10g0us1y t0 0ther kn0Wn preparati0ns Whjch are c0mmercia11y aVai1ab1e f0r the c1aimed indicati0ns , preferab1y in d0ses betWeen ab0ut 1 mg and 50 mg , in particu1ar betWeen 5 and 30 mg , per d0sage unit. The dai1y d0se is preferab1y betWeen ab0ut 0.02 and 20 mg / kg , in particu1ar 0.2 and 0.4 mg / kg , 0f b0dy Weight. [ 0043 ] HOWeVer , the speciﬁc d0se f0r each indiVidua1 patient depends 0n a Very Wide Variety 0f fact0rs , f0r eXamp1e 0n the eﬁicacy 0f the speciﬁc c0mp0und emp10yed , 0n the age , b0dy Weight , genera1 state 0f hea1th , sex , 0n the diet , 0n the time and meth0d 0f administrati0n , 0n the eXcreti0n rate , medicament c0mbinati0n and seVerity 0f the particu1ar disease t0 Which the therapy app1ies. Ora1 administrati0n is preferred. [ 0044 ] EXamp1es are giVen be10W Which serVe t0 111ustrate the inVenti0n , but d0 n0t 1imit the inVenti0n t0 the examp1es giVen. US 2006 / 0178426 A1. [ 0045 ] up” means : Water is added if necessary , the pH is adjusted , . 1n the f0110Wing examp1es , “c0nVenti0na1 W0rk - . if necessary , t0 Va1ues betWeen 2 and 10 , depending 0n the c0nstituti0n 0f the end pr0duct , the mixture is extracted With ethy1 acetate 0r dich10r0methane , the phases are separated , the 0rganic phase is dried 0Ver s0dium su1fate and eVap0 - rated , and the pr0duct is puriﬁed by chr0mat0graphy 0n si1ica ge1 and / 0r by crysta11isati0n. [ 0046 ] A11 temperatures be10W are indicated in 0 C. [ 0047 ] The f0110Wing parameters Were 0bserVed f0r ana1y - sis by HPLC MS : . [ 0048 ] C01umn : Chr0m01ith SpeedROD , 50x4.6 mm2 ( Order N0. 1.51450.0001 ) fr0m Merck. [ 0049 ] Meth0d : E1uent A : Water + 0.1% 0f TFA ( triﬁu0 - r0acetic acid ) E1uent B : acet0nitri1e + 0.08% 0f TFA. [ 0050 ] Gradient ( 1inear ) : t=0 min , A : B=80 : 20 , t=3 t0 t=3.5 min : A : B=0 : 10O. Aug. 10 , 2006. [ 0051 ] AbbreViati0ns : [ 0052 ] [ 0053 ] [ 0054 ] . M + H : M01ar peak 0f the mass spectrum MW : M01ecu1ar Weight RT : Retenti0n time. EXAMPLE 1 [ 0055 ] . [ 0056 ] A mixture 0f 25.0 g 0f amin0methy1ated p01ystyrene resin ( 0.78 mm01 / g ) , 20 mg 0f dimethy1amin0pyridine ( DMAP ) and 5.85 g 0f succinic anhydride in 200 m1 0f pyridine is stirred at r00m temperature ( RT ) f0r 0ne day , giVing after c0nVenti0na1 W0rk - up , the c0rresp0nding m0n0amide. EXAMPLE 2 [ 0057 ] . US 2006 / 0178426 A1. [ 0058 ] 3.49 g 0f 1 - ( mesity1enesu1f0ny1 ) - 3 - nitr0 - 1H - 1 , 2 , 4 - triaz01e ( MSNT ) and 4 m1 0f N - methy1imidaz01e are added With stirring t0 a mixture 0f 7.91 g 0f the m0n0amide fr0m Examp1e 1 and 4.43 g 0f the c0mp0und 1 in 120 m1 0f methy1ene ch10ride. The mixture is stirred f0r 2 h0urs. C0nVenti0na1 W0rk - up giVes the ester 2 0f the c0mp0und 1. EXAMPLE 3 [ 0059 ] | NH N / P01—\ 0 Q 0 O 3 [ 0060 ] 9.8 g 0f the ester 2 fr0m Examp1e 2 are stirred f0r. 30 minutes in 30 m1 0f piperidine and 70 m1 0f dimethy1 - . f0rmamide ( DMF ) . C0nVenti0na1 W0rk - up giVes the c0m - . p0und 3. EXAMPLE 4 [ 0061 ] | NH N / = PO1—\ 0 + 2H§1 0 O 3 0 || N\\‘O CI 0 OH. Aug. 10 , 2006. - c0ntinued 0§ ( , 0 I N N _ O P 1 O N / O —\ C1 H O O 4. [ 0062 ] 2 - ( 1 - H - benZ0triaz01 - 2y1 ) - 1 , 1 , 3 , 3 , - tetramethy1ur0nium tet - raﬁu0r0b0rates ( TBTU ) and 11.9 g 0f diis0pr0py1ety1amine are added t0 a mixture 0f 7.644 mm01 0f the c0mp0und 3 in 130 m1 0f DMF. The reacti0n mixture is stirred at RT f0r 5 h0urs. C0nVenti0na1 W0rk - up giVes the amide 4. 9.9 g 0f 2 - nitr0 - 5 - ch10r0pheny1acetic acid 14.8 g 0f. EXAMPLE 5. m>. [ 0063 ] . ﬂ?. P01—\. mz. [ 0064 ] 24.8 g 0f tin ( 1I ) ch10ride are added t0 a mixture 0f 9.4 g 0f the c0mp0und 4 in 130 m1 0f DMF , and the mixture is stirred at 500 C. f0r 6 h0urs. C0nVenti0na1W0rk - up giVes the c0mp0und 5. US 2006 / 0178426 A1 Aug. 10 , 2006. EXAMPLE 6 [ 0065 ] . @ [ mcw. C1. [ 0066 ] 0.24 g 0f 4 - ch10r0phey1 is0cyanate is added t0 a EXAMPLE 7 suspensi0n 0f 0.2 g 0f the c0mp0und 5 in 2 m1 0f methy1ene. ch10ride , and the mixture is stirred at RT f0r 18 h0urs. [ 0097 ] . C0nVenti0na1 W0rk - up giVes the c0mp0und 6. N / ww> . O. US 2006 / 0178426 A1. - c0ntinued. C1. HO. [ 0068 ] 0.8 m1 0f 4N p0tassium hydr0xide s01uti0n is added t0 a s01uti0n 0f 200 mg 0f the c0mp0und 6 in 4 m1 0f di0xane and 2 m1 0f methan01 , and the mixture is stirred at RT f0r 5 h0urs. C0nVenti0na1 W0rk - up giVes the c0mp0und. 7. EXAMPLE 8 [ 0069 ] . Aug. 10 , 2006. US 2006 / 0178426 A1. [ 0070 ] 0.291 m1 0f 4 - methy1benz0y1 ch10ride and a spatu1a tip 0f DMAP are added t0 0.15 g 0f the c0mp0und 8 in 1 m1 0f methy1ene ch10ride and 1 m1 0f pyridine. C0nVenti0na1 W0rk - up giVes the c0mp0und 9. EXAMPUE9 [ 0071 ] . 10. [ 0072 ] A mixture 0f 150 mg 0f the c0mp0und 9 , 3.5 m1 0f di0xane , 1.8 m1 0f methan01 and 0.7 m1 0f 4N p0tassium hydr0xide s01uti0n is stirred at r00m temperature f0r 5 h0urs. C0nVenti0na1 W0rk - up giVes the c0mp0und 10. EXAMPLE 11. O l NH2 II @N O=S—C1 P 1 O N / O W 9 O. O. [ 0073 ] . 11. Aug. 10 , 2006. US 2006 / 0178426 A1 Aug. 10 , 2006. - c0ntinued. O. HN / S\O : “ID ; 6 P01—\ 0 Q 1H O. O 12. [ 0074 ] 473 mg 0f 2 , 4 , 6 - triis0pr0py1benzenesu1f0ny1 ch10 - EXAMPLE 12 ride and a spatu1a tip 0f DMAP are added t0 0.20 g 0f the. c0mp0und 11 in 1 m1 0f methy1ene ch10ride and 1 m1 0f. pyridine. The mixture is stirred f0r 3 h0urs. C0nVenti0na1. W0rk - up giVes the c0mp0und 12. [ 0075 ] . 0. || . S. E ] HN / %O 7D j 0 Po1—\ 0 Q o. O 12. US 2006 / 0178426 A1. - c0ntinued. 13. [ 0076 ] A mixture 0f 200 mg 0f the c0mp0und 12 , 4 m1 0f di0xane , 2 m1 0f methan01 and 0.8 m1 0f 4N p0tassium hydr0xide s01uti0n is stirred at r00m temperature f0r 5 h0urs. C0nVenti0na1 W0rk - up giVes the c0mp0und 13. [ 0077 ] The f0110Wing c0mp0unds acc0rding t0 the inVen - ti0n are 0btainab1e by using the c0rresp0nding precurs0rs : . . . Ref. N0. RT ( min ) M + H 387714 QH Chira1 1.40 588 O A @930 / \0 O N / HO 387721 Chira1 1.72 570. H3C CH3 0 / |S| mo cH3 HQ / . Aug. 10 , 2006. US 2006 / 0178426 A1 10. - c0ntinued. Aug. 10 , 2006. . RﬁL : NQ. RT ( nnn ) N1 + 11. . 0. 387731 Chira1 I O . 33. HI ) . 387732 3 Chira1. 33. \C / J. =O. 222. H0 337733 C1 Chira1 0 N / |s| C1 @cmO / \0 HO 337734 Chira1. L91 612 L61 578 L71 597 L67 596. US 2006 / 0178426 A1 Aug. 10 , 2006 11. - c0ntinued. . Ref. N0. RT ( min ) M + H. . 3 8773 5 Chjra ] 1.83 600 H3. N C1 HO 337736 Ch ] m1 1.50 533 0 \CH3 0 E o | CH3 N ' 0 N / C1 HO 337737 mm 2.19 654 CH3 CH3 H3C ( : H3. 3 CH3 \0 H3C ( : 13 : 3 Q / TO. HO. US 2006 / 0178426 A1. Aug. 10 , 2006. . . 1 2 - c0ntinued Ref. N0. RT ( min ) M + H 387738 Chira1 1.82 584 CH3 CH3 0 CH3 || N / k Q ; HO 337739 cH3 mm 1.70 600 H C O 3 \CH3 0 S“ CH CU : 00 3 Q / HO 387743 Chira1 1.58 541. CI 0 210. 9. HO. US 2006 / O178426 A1 Aug. 10 , 2006 13. - c011ti11ued. . Ref. N0. RT ( min ) M + H. . 387744 Chm 1.70 591. @. Q. HO. 387745 Chira1 1.41 532. 11?. Q. HO. 387748 Ch1ra1 1.67 575. QQ Q. 388748 Chira1 1.68 566. “\O : .0WCH3. =O. © ( fH3. m. HO. US 2006 / O178426 A1. Aug. 10 , 2006. . . 14 - c0ntinued Ref. N0. RT ( min ) M + H 388750 CH3 Chira1 1.55 566 H C O 3 \CH3 0 8 CH3 CH3 N / \O I m N _ O Q / HO 388753 Chira1 1.65 578 O H 0 a S CH3 N / \\‘O U Nm _ O Q / HO 388756 Chm 1.54 536 H3C CH3. mm M OO I m CH3 N. Q / 0. HO. 0 II. S. US 2006 / O178426 A1 Aug. 10 , 2006 15. - c0ntinued. . Ref. N0. RT ( min ) M + H. . 388758 Chira1 1.22 554. 388808 Chiral 1.54 562. O. / / CO. HO. / >m=O Q Q. HO. 388809146 541. HO. US 2006 / O178426 A1. Aug. 10 , 2006. . . 16 - c011ti11ued Ref. N0. RT ( m1n ) M + H 388810 mm 1.21 554 O \CH3 O E 0 | m CH3 N _ O Q / HO 388811 Chira1 1.46 544 O 8 CH3 N / \0 I m N _ O Q / HO 388813 Ch1ra1 1.16 498 O %N CH3 NiN | m N _ O Q / HO 388814 Ch1ra1 1.47 557. US 2006 / O178426 A1. Aug. 10 , 2006. . . - c011ti11ued Ref. N0. RT ( m1n ) M + H 388815 Chira1 1.33 507 C1 O g A NmA© _ O Q / HO 390485 Chira1 1.64 550 CH3 CH3 0 CH3 1 CH3 N / \‘0 I m N _ O Q / HO 390486 Chira1 2.05 620 CH3 CH3 H3C CH3 O 8 CH3 N / \0 1L7‘ / \© H3C CH3 _ O Q / HO 391182 Chm 1.58 541 CH3 F O\ / I F i F. US 2006 / O178426 A1. 18. Aug. 10 , 2006. . . - c011ti11ued Ref. N0. RT ( m1n ) M + H 391183 CH3 Ch1ra1 1.47 507 111 C1 m 0 U = o A Q / N N HO 391185 mm 1.42 541 F F 0 U‘ A &NT\O / N N _ O Q / HO 391186 mm 1.47 507 C1 0 A @Nm / N N - O Q / HO 391193 CH3 Ch1ra1 1.56 550 CH3 CH3 A CH3 : O ; m H HO 391194 Chira1 1.50 562. . . US 2006 / O178426 A1 Aug. 10 , 2006 19 - c011ti11ued Ref N0. RT ( m1n ) M + H 391195 Chira1 1.33 472 ©3130 391196 H©\ / CH3 Ch1ra1 1.55 526 N / : NmN N ) k© : : 391203 Chira1 1.61 550 CH3 CH3 O CH3 || ©\_ / L N / KO d 60 HO 391204 Ch1ra1 1.49 562. ( : 113 1. 9 HO. US 2006 / 0178426 A1. 20. Aug. 10 , 2006. . . . - c0ntinued Ref. N0. RT ( min ) M + H 391205 0 mm 1.31 472 CH3 1 “U Q m HO 391207 0 mm 1.54 526 mi I kgCl N N Q m . HO [ 0078 ] The pharmaceutica1 eﬁicacy 0f the substances EXAMPLE E acc0rding t0 the inVenti0n in the treatment 0f irritab1e b0We1 syndr0me can be inVestigated by the meth0d described in Tab1ets. Eur0pean J. 0f Pharmac010gy 271 ( 1994 ) 245 - 251. The f0110Wing examp1es re1ate t0 pharmaceutica1 c0mp0siti0ns : . EXAMPLE A. Injecti0n Via1s. [ 0079 ] A s01uti0n 0f 100 g 0f an actiVe ingredient 0f the f0rmu1a I and 5 g 0f dis0dium hydr0genph0sphate in 3 1 0f bidisti1led Water are adjusted t0 pH 6.5 using 2 N hydr0 - ch10ric acid , steri1e - ﬁ1tered , transfe1red int0 injecti0n Via1s , 1y0phi1ised under steri1e c0nditi0ns and sea1ed under steri1e c0nditi0ns. Each injecti0n Via1 c0ntains 5 mg 0f active ingredient. EXAMPLE B. Supp0sit0ries. [ 0080 ] A miXture 0f 20 g 0f an actiVe ingredient 0f the f0rmu1a I With 100 g 0f s0ya lecithin and 1400 g 0f c0c0a butter is me1ted , p0ured int0 m0u1ds and a1l0Wed t0 c001. Each supp0sit0ry c0ntains 20 mg 0f actiVe ingredient. EXAMPLE C. S01uti0n. [ 0081 ] A s01uti0n is prepared fr0m 1 g 0f an actiVe ingredient 0f the f0rmu1a 1 , 9.38 g 0f NaH2PO4 , 2H2O , 28.48 g 0f Na2HPO4 , 12H2O , and 0.1 g 0f benza1k0nium ch10ride in 940 m1 0f bidisti11ed Water. The pH is adjusted t0 6.8 , and the s01uti0n is made up t0 1 1 and steri1ised by irradiati0n. EXAMPLE D. Ointment. [ 0082 ] 500 mg 0f an actiVe ingredient 0f the f01mu1a I are mixed With 99.5 g 0f Vase1ine under aseptic c0nditi0ns. [ 0083 ] A miXture 0f 1 kg 0f actiVe ingredient 0f the f0rmu1a I , 4 kg 0f 1act0se , 1.2 kg 0f p0tat0 starch , 0.2 kg 0f ta1c and 0.1 kg 0f magnesium stearate is pressed in a c0nVenti0na1 manner t0 giVe tab1ets in such a Way that each tab1et c0ntains 10 mg 0f actiVe ingredient. EXAMPLE F. Dragees. [ 0084 ] Tab1ets are pressed ana10g0us1y t0 Examp1e E and subsequent1y c0ated in a c0nVenti0na1 manner With a c0ating 0f sucr0se , p0tat0 starch , ta1c , tragacanth and dye. 1. C0mp0unds f0rmu1a 1. I \ R3 ( R1 ) m—| ] N—X—Y—A / \\ . I j N ( R2 ) HO. US 2006 / 0178426 A1. in Which. A den0tes a m0n0 - 0r bicyclic ar0matic 0r n0n - ar0matic carba - 0r heter0cyc1ic ring system Which is unsubstituted 0r m0n0 - 0r p01ysubstituted by R1 , . R1 den0tes H , Ha1 , NO2 , NHR , NRR , OR , CO7R , SO3R , SO2R , SR , CF3 , OCF3 , SCF3 , C1 - C8 a1ky1 , C3 - Cl4 cyc10a1ky1 , . R2 den0tes H , Ha1 , NO2 , NHR , NRR , OR , CO7R , SO3R , SO2R , SR , CF3 , OCF3 , SCF3 , C1 - C8 a1ky1 , C3 - C14 cyc10a1ky1 , . R3 den0tes C1 - C8 alky1 , X den0tes CO , CS , SO2 , Y den0tes a sing1e b0nd , O , NH , CH2. R den0tes H 0r a C1 - C8 a1ky1 , C3 - Cl4 cyc10a1ky1 , C6 ' C1o ary1 0r C7 - Cl4 ara1kyI gr0up , Which may be m0n0 - 0r p01ysubstituted by R5 and Wh0 se a1ky1 - C chain may be interrupted by —O— , . Hal den0tes F , C1 , Br , 0r I m den0tes 0 , 1 , 2 , 3 0r 4 and. n den0tes 0 , 1 , 2 0r 3 , . and pharmaceutica11y usab1e deriVatiVes , s01Vates and stere0is0mers there0f , eXc1usiVe1y miXtures there0f in a11 rati0s. 2. C0mp0unds 0f the f0rmu1a IA. IA 1 \ R3 ( R1 ) ...—| / 111 N—X—Y—A \\ | j _ O / / \<R2>. HO. 21. Aug. 10 , 2006. in Which Rl , R2 , R3 , X , Y , A , m and n haVe the meaning indicated in c1aim 1 , and phannac0l0gica1 usab1e deriVatiVes , sa1ts , s01Vates and stere0is0mers there0f and miXtures there0f in a1l rati0s. 3. C0mp0und 0f the f0rmu1a I and IA , acc0rding t0 c1aim 1 in Which. A den0tes phenyl , pyridy1 , thieny1 0r cyc10heXyl , each 0f Which is unsubstituted 0r m0n0 - 0r p01ysubstituted by R a. R1 den0tes H. R2 den0tes H 0r Ha1. 4. Medicament 0f the f0nnuIa I acc0rding t0 c1aim 1 in Which. A den0tes pheny1 0r naphthyI and / 0r. X den0tes CO 0r SO2. and / 0r. Y den0tes a sing1e b0nd 0r NH. 5. Use 0f the c0mp0unds 0f the f0rmu1a I and / 0r IA acc0rding t0 c1aim 1 and physi010gica11y acceptab1e sa1ts , s01Vates and deriVatiVes there0f f0r the preparati0n 0f medicaments f0r the treatment and / 0r pr0phy1axis 0f irritabIe b0We1 syndr0me. 6. Pharmaceutica1 00mp0siti0n , characterised by a c0ntent 0f at 1east 0ne c0mp0und 0f the f0rmu1a I and / 0r IA and / 0r 0ne 0f its physi010gica11y acceptab1e saIts , sOIVates and deriVatiVes acc0rding t0 c1aim 1 f0r the treatment and / 0r pr0phy1aXis 0f irritab1e b0We1 syndr0me. 7. C0mp0unds 0f the f01mu1a I acc0rding t0 c1aim 1 and acceptab1e sa1ts , s0lVates and deriVatiVes there0f as medicaments. 8. Use 0f the c0mp0unds 0f the f0rmuIa I and / 0r IA acc0rding t0 c1aim 1 and physi010gica11y acceptab1e sa1ts , s01Vates and deriVatiVes there0f f0r the preparati0n 0f medicaments f0r the treatment and / 0r pr0phy1aXis 0f diseases Which can be inﬂuenced by kappa ag0nists. 9. Medicament f0rmuIati0n c0mprising at Ieast 0ne c0m - p0und 0f the f0rmu1a I and 0r IA acc0rding t0 c1aim 1 and / 0r pharmaceutica11y usab1e deriVatiVes , s01Vates and stere0is0 - mers there0f , inc1uding miXtures there0f in a11 rati0s. * * $ $ *